Role of Toll-like receptor 4 in intravascular hemolysis-mediated injury.
TLR4
acute kidney injury
heme
hemoglobin
inflammation
intravascular hemolysis
oxidative stress
Journal
The Journal of pathology
ISSN: 1096-9896
Titre abrégé: J Pathol
Pays: England
ID NLM: 0204634
Informations de publication
Date de publication:
11 2022
11 2022
Historique:
revised:
17
07
2022
received:
29
01
2022
accepted:
25
07
2022
pubmed:
30
7
2022
medline:
6
10
2022
entrez:
29
7
2022
Statut:
ppublish
Résumé
Massive intravascular hemolysis is a common characteristic of several pathologies. It is associated with the release of large quantities of heme into the circulation, promoting injury in vulnerable organs, mainly kidney, liver, and spleen. Heme activates Toll-like receptor 4 (TLR4), a key regulator of the inflammatory response; however, the role of TLR4 in hemolysis and whether inhibition of this receptor may protect from heme-mediated injury are unknown. We induced intravascular hemolysis by injection of phenylhydrazine in wildtype and Tlr4-knockout mice. In this model, we analyzed physiological parameters, histological damage, inflammation and cell death in kidney, liver, and spleen. We also evaluated whether heme-mediated-inflammatory effects were prevented by TLR4 inhibition with the compound TAK-242, both in vivo and in vitro. Induction of massive hemolysis elicited acute kidney injury characterized by loss of renal function, morphological alterations of the tubular epithelium, cell death, and inflammation. These pathological effects were significantly ameliorated in the TLR4-deficient mice and in wildtype mice treated with TAK-242. In vitro studies showed that TAK-242 pretreatment reduced heme-mediated inflammation by inhibiting the TLR4/NF-κB (nuclear factor kappa B) axis. However, analysis in liver and spleen indicated that TLR4 deficiency did not protect against the toxic accumulation of heme in these organs. In conclusion, TLR4 is a key molecule involved in the renal inflammatory response triggered by massive intravascular hemolysis. TLR4 inhibition may be a potential therapeutic approach to prevent renal damage in patients suffering from hemolysis. © 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Substances chimiques
NF-kappa B
0
Phenylhydrazines
0
Sulfonamides
0
Tlr4 protein, mouse
0
Toll-Like Receptor 4
0
ethyl 6-(N-(2-chloro-4-fluorophenyl)sulfamoyl)cyclohex-1-ene-1-carboxylate
0
Heme
42VZT0U6YR
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
236-249Informations de copyright
© 2022 The Authors. The Journal of Pathology published by John Wiley & Sons Ltd on behalf of The Pathological Society of Great Britain and Ireland.
Références
Blood. 2014 Jan 16;123(3):377-90
pubmed: 24277079
Blood. 2002 Jun 1;99(11):4160-5
pubmed: 12010821
Nat Med. 2002 Dec;8(12):1383-9
pubmed: 12426562
J Lab Clin Med. 1990 Oct;116(4):498-507
pubmed: 2212859
Am J Pathol. 2001 Mar;158(3):893-903
pubmed: 11238038
J Am Soc Nephrol. 2007 Feb;18(2):414-20
pubmed: 17229906
Br J Haematol. 2014 Jul;166(2):165-76
pubmed: 24862308
Blood Adv. 2019 Sep 10;3(17):2679-2687
pubmed: 31506286
Acta Physiol (Oxf). 2017 Mar;219(3):573-588
pubmed: 27602552
J Cereb Blood Flow Metab. 2015 Mar 31;35(4):536-42
pubmed: 25586141
Front Immunol. 2015 Sep 22;6:480
pubmed: 26441984
Ann Med. 2004;36(5):347-54
pubmed: 15478309
Arch Toxicol. 2017 Apr;91(4):1925-1939
pubmed: 27585667
Toxicon. 2019 May;163:23-31
pubmed: 30890325
FASEB J. 2019 Aug;33(8):8961-8975
pubmed: 31034781
Clin Gastroenterol Hepatol. 2007 Dec;5(12):1469-76; quiz 1369
pubmed: 17900995
Expert Rev Hematol. 2019 Jul;12(7):563-573
pubmed: 31195851
PLoS One. 2012;7(5):e37584
pubmed: 22655058
Am J Kidney Dis. 2008 Nov;52(5):972-7
pubmed: 18805612
Curr Med Sci. 2021 Jun;41(3):572-580
pubmed: 34047945
Crit Care. 2014 Sep 03;18(5):488
pubmed: 25182709
J Biol Chem. 2007 Jul 13;282(28):20221-9
pubmed: 17502383
Blood. 2010 Dec 23;116(26):6054-62
pubmed: 20844238
Proc Soc Exp Biol Med. 1997 Dec;216(3):456-63
pubmed: 9402154
Proc Natl Acad Sci U S A. 2019 Mar 26;116(13):6280-6285
pubmed: 30850533
Semin Hematol. 1989 Apr;26(2):105-13
pubmed: 2658086
Free Radic Biol Med. 2015 Dec;89:931-43
pubmed: 26475040
Mol Med Rep. 2019 Sep;20(3):2101-2110
pubmed: 31257518
Int J Cardiol. 2015 Dec 15;201:66-78
pubmed: 26296046
J Biol Chem. 2012 Aug 3;287(32):26630-46
pubmed: 22696214
Front Pharmacol. 2014 May 27;5:115
pubmed: 24904418
Am J Pathol. 2000 May;156(5):1527-35
pubmed: 10793064
Antioxid Redox Signal. 2016 Jul 20;25(3):165-83
pubmed: 26906116
Nat Med. 2016 Aug;22(8):945-51
pubmed: 27428900
J Am Soc Nephrol. 2008 May;19(5):923-32
pubmed: 18256356
Nat Rev Nephrol. 2019 Nov;15(11):671-692
pubmed: 31455889
Front Pharmacol. 2019 Jul 03;10:740
pubmed: 31333462
Int J Mol Sci. 2021 Jan 15;22(2):
pubmed: 33467524
Front Immunol. 2020 Jun 23;11:1309
pubmed: 32655575
Turk J Gastroenterol. 2005 Dec;16(4):194-8
pubmed: 16547846
Nat Med. 2018 Feb;24(2):232-238
pubmed: 29309057
J Clin Invest. 1992 Jul;90(1):267-70
pubmed: 1634613
Lancet. 2008 Oct 18;372(9647):1411-26
pubmed: 18940465
PLoS One. 2008;3(10):e3596
pubmed: 18974879
J Am Soc Nephrol. 2017 Jan;28(1):218-229
pubmed: 27352622
Arch Biochem Biophys. 2019 Sep 15;672:108075
pubmed: 31412260
Hepatology. 1988 Jan-Feb;8(1):32-8
pubmed: 3338718
Nefrologia (Engl Ed). 2018 Jan - Feb;38(1):13-26
pubmed: 28668175
J Cell Biol. 1988 Oct;107(4):1359-68
pubmed: 3170633
Toxicol Sci. 2019 Dec 1;172(2):385-397
pubmed: 31504964
Int J Clin Exp Pathol. 2018 Feb 01;11(2):1054-1061
pubmed: 31938201
Aliment Pharmacol Ther. 2015 Oct;42(7):912-21
pubmed: 26235444
Front Immunol. 2017 Feb 02;8:73
pubmed: 28210260
Am J Physiol Renal Physiol. 2004 Feb;286(2):F370-7
pubmed: 14707007
Mol Pharmacol. 2011 Jan;79(1):34-41
pubmed: 20881006
Blood. 2002 Dec 1;100(12):4201-8
pubmed: 12393471